Literature DB >> 1808610

In vitro and in vivo evaluation of whole and half tablets of sustained-release adinazolam mesylate.

J W Skoug1, M T Borin, J C Fleishaker, A M Cooper.   

Abstract

The mechanism of release from sustained-release adinazolam mesylate tablets was assessed by the Higuchi equation and by analysis of drug release profiles through 60% released using the Peppas equation. Computed values of the diffusional exponent, n, ranged from 0.59 to 0.66. Values of n in this range are consistent with a mixed mechanism of release, with diffusion of drug through the hydrated polymer matrix and relaxation of this matrix being the principal processes controlling release. The rate of in vitro drug release was increased for half tablets relative to whole tablets and is attributed to an increase in the surface to volume ratio of half tablets of about 16%. This increase in surface-to-volume ratio of half tablets was reflected by an increase in the constant, k, from the Peppas equation of 20-23% and by an increase in the slope of Higuchi plots of 12-18% for four lots of tablets. In vivo/in vitro relationships from two bioavailability studies were thoroughly evaluated. Using either a linear or a quadratic relationship, an in vivo/in vitro correlation exists for sustained-release adinazolam mesylate tablets.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1808610     DOI: 10.1023/a:1015834114359

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

1.  Analysis of data on the medicament release from ointments.

Authors:  W I HIGUCHI
Journal:  J Pharm Sci       Date:  1962-08       Impact factor: 3.534

2.  Report of the workshop on in vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms.

Authors:  J P Skelley; G L Amidon; W H Barr; L Z Benet; J E Carter; J R Robinson; V P Shah; A Yacobi
Journal:  J Pharm Sci       Date:  1990-09       Impact factor: 3.534

3.  Analysis of in vitro dissolution of whole vs. half controlled-release theophylline tablets.

Authors:  V P Shah; L A Yamamoto; D Schuirman; J Elkins; J P Skelly
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

4.  A novel approach to the specification of in-vitro dissolution boundaries based on regulatory requirements for bioequivalence.

Authors:  V W Steinijans; R Dietrich; H Trautmann; R Sauter; G Benedikt
Journal:  Arzneimittelforschung       Date:  1988-08

5.  Pharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equation.

Authors:  J G Wagner
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

6.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate after single oral doses of each compound in healthy volunteers.

Authors:  J C Fleishaker; H Friedman; S R Pollock; T C Smith
Journal:  Clin Pharmacol Ther       Date:  1990-12       Impact factor: 6.875

8.  Adinazolam--a new antidepressant: findings of a placebo-controlled, double-blind study in outpatients with major depression.

Authors:  D Dunner; J Myers; A Khan; D Avery; D Ishiki; R Pyke
Journal:  J Clin Psychopharmacol       Date:  1987-06       Impact factor: 3.153

9.  Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects.

Authors:  J C Fleishaker; J P Phillips; T C Smith; R B Smith
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

10.  Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders.

Authors:  R E Pyke; H S Greenberg
Journal:  J Clin Psychopharmacol       Date:  1989-02       Impact factor: 3.153

View more
  1 in total

1.  Diffusion in HPMC gels. II. Prediction of drug release rates from hydrophilic matrix extended-release dosage forms.

Authors:  P Gao; P R Nixon; J W Skoug
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.